As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Market expert Daljeet Kohli advises investors to focus on quality stocks at discounted prices, rather than the Nifty's movement. He highlig...

Corporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...

Markets closed lower amid geopolitical tensions, rupee weakness, and rising inflation. Upcoming week will be sensitive to US-Iran conflict ...

Indian markets face ongoing turbulence, with a slowdown imminent due to inflation and supply chain issues. Foreign investors are selling of...

Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business press...

Markets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...

Emcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in I...

India's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...

Corporate India faces heightened uncertainty entering fiscal year 2026-27 due to geopolitical tensions and AI disruption. Sectors like bank...

Biocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...

India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...

Leading drugmakers including Sun Pharmaceuticals, Dr Reddy’s Laboratories, Zydus Lifesciences, Natco Pharma, Eris Lifesciences, USV, Glenma...

India is set to experience a dramatic shift as Ozempic and Wegovy's active ingredient, semaglutide, becomes widely available. Over 40 India...

Dr Reddy's Laboratories is set to launch a generic version of semaglutide in India on March 21. The company plans to offer both oral and in...

Drug maker Lupin announced a significant partnership. Its subsidiary, Lupin Atlantis Holdings SA, has signed an agreement with Galenicum He...

Indian drugmakers, including Dr. Reddy's and Zydus Lifesciences, are investing heavily in manufacturing capabilities to launch generic vers...